Bettaieb A, Fromont P, Louache F, Oksenhendler E, Vainchenker W, Duédari N, Bierling P
Centre de Transfusion, INSERM U91, Hôpital Henri Mondor, Créteil, France.
Blood. 1992 Jul 1;80(1):162-9.
We previously reported the presence in platelet eluates of autoantibodies directed against epitopes of the platelet glycoprotein (GP)IIb/IIIa complex in acquired immunodeficiency syndrome (AIDS)-free human immunodeficiency virus (HIV)-infected patients with immunologic thrombocytopenic purpura (ITP). We investigated whether HIV antibodies recognized platelet membrane antigens to determine whether the virus might be directly or indirectly responsible for the thrombocytopenia in this context. Direct eluates of platelets from 25 patients with HIV-related ITP contained IgG reacting with HIV-GP160/120 and also, in 45% of patients, detectable antiplatelet antibodies, immunochemically characterized as anti-GPIIb and/or anti-GPIIIa in 5 patients. Furthermore, serum HIV-GP160/120 antibodies could be absorbed on and eluted from platelets from normal non-HIV-infected healthy blood donors (indirect eluates). In contrast, GP160/120 antibodies present in the serum of nonthrombocytopenic HIV-infected patients were not absorbable on normal platelets in most patients, suggesting a pathogenic role in HIV-related ITP. We performed detailed studies of a patient with the highest titer of both HIV-GP160/120 and GPIIb/IIIa antibodies in direct and indirect platelet eluates. No antibody binding to GPIIb/IIIa-deficient Glanzmann thrombasthenic platelets was detected. Furthermore, binding/elution experiments conducted with insoluble recombinant GP160 (expressed in baculovirus) and purified platelet GPIIb/IIIa demonstrated that the patient's IgG bound specifically, through the F(ab')2 portion, to a common epitope of HIV-GP160/120 and platelet GPIIb/IIIa. This common epitope was present on a recombinant GP160 expressed in baculovirus but absent from another recombinant GP160 expressed in vaccinia virus, suggesting that the cross-reactivity is dependent on the glycosylation or conformational structure of the GP. We conclude that molecular mimicry between HIV-GP160/120 and platelet GPIIb/IIIa may explain at least some cases of ITP in AIDS-free HIV-infected patients.
我们之前报道过,在无获得性免疫缺陷综合征(AIDS)的人类免疫缺陷病毒(HIV)感染且患有免疫性血小板减少性紫癜(ITP)的患者的血小板洗脱液中,存在针对血小板糖蛋白(GP)IIb/IIIa复合物表位的自身抗体。我们研究了HIV抗体是否识别血小板膜抗原,以确定在这种情况下该病毒是否可能直接或间接导致血小板减少。来自25例HIV相关ITP患者的血小板直接洗脱液中含有与HIV-GP160/120发生反应的IgG,并且在45%的患者中还可检测到抗血小板抗体,其中5例患者的抗血小板抗体经免疫化学鉴定为抗GPIIb和/或抗GPIIIa。此外,血清中的HIV-GP160/120抗体可被正常未感染HIV的健康献血者的血小板吸附并洗脱下来(间接洗脱液)。相比之下,大多数非血小板减少性HIV感染患者血清中的GP160/120抗体不能被正常血小板吸附,这表明其在HIV相关ITP中具有致病作用。我们对一名在直接和间接血小板洗脱液中HIV-GP160/120和GPIIb/IIIa抗体滴度最高的患者进行了详细研究。未检测到抗体与缺乏GPIIb/IIIa的Glanzmann血小板无力症血小板结合。此外,用不溶性重组GP160(在杆状病毒中表达)和纯化的血小板GPIIb/IIIa进行的结合/洗脱实验表明,该患者的IgG通过F(ab')2部分特异性结合到HIV-GP160/120和血小板GPIIb/IIIa的一个共同表位上。这个共同表位存在于杆状病毒中表达的重组GP160上,但不存在于痘苗病毒中表达的另一种重组GP160上,这表明交叉反应性取决于GP的糖基化或构象结构。我们得出结论,HIV-GP160/120与血小板GPIIb/IIIa之间的分子模拟可能至少解释了部分无AIDS的HIV感染患者的ITP病例。